Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 294,145 |
|
|||||
| News | - | ||||||
| Day High | 8.1701 | Low High |
|||||
| Day Low | 7.85 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 0.62% | 8.06 | 08:58:33 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.01 | 7.85 | 8.1701 | 8.01 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,010 | 294,145 | US$ 8.04 | US$ 2,365,961 | - | 2.09 - 14.84 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 08:58:32 | 164 | US$ 8.06 | USD |
Altimmune (ALT) Options Flow Summary
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 430.37M | 53.73M | - | 426k | -88.45M | -1.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Altimmune News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.32 | 9.50 | 7.115 | 8.30 | 3,595,709 | 0.74 | 10.11% |
| 1 Month | 7.03 | 9.50 | 6.282 | 7.48 | 3,125,963 | 1.03 | 14.65% |
| 3 Months | 10.44 | 14.84 | 6.282 | 9.66 | 4,426,767 | -2.38 | -22.80% |
| 6 Months | 2.44 | 14.84 | 2.41 | 8.06 | 8,097,752 | 5.62 | 230.33% |
| 1 Year | 4.545 | 14.84 | 2.09 | 7.31 | 4,753,931 | 3.52 | 77.34% |
| 3 Years | 14.01 | 23.49 | 2.09 | 8.81 | 2,609,499 | -5.95 | -42.47% |
| 5 Years | 2.41 | 35.10 | 1.45 | 10.02 | 2,176,696 | 5.65 | 234.44% |
Altimmune Description
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |
